Atox Bio is a late-stage biotechnology company specializing in the development of novel immunomodulators for critically ill patients. The company's lead product, Reltecimod, is designed to treat Necrotizing Soft Tissue Infections (NSTI), a rare and life-threatening condition. Atox Bio recently completed a Phase 3 clinical trial for Reltecimod in NSTI patients and is currently conducting another Phase 3 study for Acute Kidney Injury (AKI). Additional indications are in preclinical stages. The company primarily serves healthcare providers and operates within the biopharmaceutical market. Atox Bio's business model revolves around the research, development, and commercialization of its proprietary treatments. Revenue is generated through the successful development and eventual sale or licensing of its therapeutic products.

Keywords: biotechnology, immunomodulators, clinical trials, NSTI, AKI, Reltecimod, healthcare, biopharmaceutical, critical conditions, novel treatments.